Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response

Rolf Kreutz, Jeffrey Breall, Yvonne Kreutz, Janelle Owens, Deshun Lu, Islam Bolad, Elisabeth von der Lohe, Anjan Sinha, David A. Flockhart

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: Clopidogrel inhibits ADP mediated platelet aggregation through inhibition of the P2Y12 receptor by its active metabolite. Thrombin induces platelet aggregation by binding to protease activated receptor-1 (PAR-1), and inhibition of PAR-1 has been evaluated in patients treated with clopidogrel to reduce ischemic events after acute coronary syndromes. Residual PAR-1 mediated platelet aggregation may be dependent on extent of clopidogrel response. Material and Methods: Platelet aggregation was measured in 55 patients undergoing elective PCI at 16-24 hours after 600 mg clopidogrel loading dose by light transmittance aggregometry using ADP 20 μM and thrombin receptor agonist peptide (TRAP) at 15 μM and 25 μM as agonists. Genomic DNA was genotyped for common CYP2C19 variants. Results: Increasing quartiles of 20 μM ADP induced platelet aggregation after clopidogrel loading were associated with increasing levels of TRAP mediated platelet aggregation. Patients in the highest quartile (clopidogrel non-responders) of post treatment ADP aggregation had significantly higher TRAP mediated aggregation than the patients in the lowest quartile (clopidogrel responders) [TRAP 15 μM: 79.6 ± 5% vs. 69.5 ± 8%, p < 0.001]. Conclusions: Non-responders to clopidogrel show increased residual platelet aggregation induced by TRAP, whereas clopidogrel responders exhibit attenuated response to TRAP. Addition of PAR-1 antiplatelet drugs may be most effective in patients with reduced clopidogrel response and high residual TRAP mediated platelet aggregation.

Original languageEnglish
Pages (from-to)198-202
Number of pages5
JournalThrombosis Research
Volume130
Issue number2
DOIs
StatePublished - Aug 2012

Fingerprint

clopidogrel
PAR-1 Receptor
Platelet Aggregation
Thrombin Receptors
Adenosine Diphosphate
Peptides

Keywords

  • aggregation
  • clopidogrel
  • Platelet
  • thrombin

ASJC Scopus subject areas

  • Hematology

Cite this

Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response. / Kreutz, Rolf; Breall, Jeffrey; Kreutz, Yvonne; Owens, Janelle; Lu, Deshun; Bolad, Islam; von der Lohe, Elisabeth; Sinha, Anjan; Flockhart, David A.

In: Thrombosis Research, Vol. 130, No. 2, 08.2012, p. 198-202.

Research output: Contribution to journalArticle

@article{56232af471a94424bc43fb93625a22ba,
title = "Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response",
abstract = "Introduction: Clopidogrel inhibits ADP mediated platelet aggregation through inhibition of the P2Y12 receptor by its active metabolite. Thrombin induces platelet aggregation by binding to protease activated receptor-1 (PAR-1), and inhibition of PAR-1 has been evaluated in patients treated with clopidogrel to reduce ischemic events after acute coronary syndromes. Residual PAR-1 mediated platelet aggregation may be dependent on extent of clopidogrel response. Material and Methods: Platelet aggregation was measured in 55 patients undergoing elective PCI at 16-24 hours after 600 mg clopidogrel loading dose by light transmittance aggregometry using ADP 20 μM and thrombin receptor agonist peptide (TRAP) at 15 μM and 25 μM as agonists. Genomic DNA was genotyped for common CYP2C19 variants. Results: Increasing quartiles of 20 μM ADP induced platelet aggregation after clopidogrel loading were associated with increasing levels of TRAP mediated platelet aggregation. Patients in the highest quartile (clopidogrel non-responders) of post treatment ADP aggregation had significantly higher TRAP mediated aggregation than the patients in the lowest quartile (clopidogrel responders) [TRAP 15 μM: 79.6 ± 5{\%} vs. 69.5 ± 8{\%}, p < 0.001]. Conclusions: Non-responders to clopidogrel show increased residual platelet aggregation induced by TRAP, whereas clopidogrel responders exhibit attenuated response to TRAP. Addition of PAR-1 antiplatelet drugs may be most effective in patients with reduced clopidogrel response and high residual TRAP mediated platelet aggregation.",
keywords = "aggregation, clopidogrel, Platelet, thrombin",
author = "Rolf Kreutz and Jeffrey Breall and Yvonne Kreutz and Janelle Owens and Deshun Lu and Islam Bolad and {von der Lohe}, Elisabeth and Anjan Sinha and Flockhart, {David A.}",
year = "2012",
month = "8",
doi = "10.1016/j.thromres.2012.02.049",
language = "English",
volume = "130",
pages = "198--202",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response

AU - Kreutz, Rolf

AU - Breall, Jeffrey

AU - Kreutz, Yvonne

AU - Owens, Janelle

AU - Lu, Deshun

AU - Bolad, Islam

AU - von der Lohe, Elisabeth

AU - Sinha, Anjan

AU - Flockhart, David A.

PY - 2012/8

Y1 - 2012/8

N2 - Introduction: Clopidogrel inhibits ADP mediated platelet aggregation through inhibition of the P2Y12 receptor by its active metabolite. Thrombin induces platelet aggregation by binding to protease activated receptor-1 (PAR-1), and inhibition of PAR-1 has been evaluated in patients treated with clopidogrel to reduce ischemic events after acute coronary syndromes. Residual PAR-1 mediated platelet aggregation may be dependent on extent of clopidogrel response. Material and Methods: Platelet aggregation was measured in 55 patients undergoing elective PCI at 16-24 hours after 600 mg clopidogrel loading dose by light transmittance aggregometry using ADP 20 μM and thrombin receptor agonist peptide (TRAP) at 15 μM and 25 μM as agonists. Genomic DNA was genotyped for common CYP2C19 variants. Results: Increasing quartiles of 20 μM ADP induced platelet aggregation after clopidogrel loading were associated with increasing levels of TRAP mediated platelet aggregation. Patients in the highest quartile (clopidogrel non-responders) of post treatment ADP aggregation had significantly higher TRAP mediated aggregation than the patients in the lowest quartile (clopidogrel responders) [TRAP 15 μM: 79.6 ± 5% vs. 69.5 ± 8%, p < 0.001]. Conclusions: Non-responders to clopidogrel show increased residual platelet aggregation induced by TRAP, whereas clopidogrel responders exhibit attenuated response to TRAP. Addition of PAR-1 antiplatelet drugs may be most effective in patients with reduced clopidogrel response and high residual TRAP mediated platelet aggregation.

AB - Introduction: Clopidogrel inhibits ADP mediated platelet aggregation through inhibition of the P2Y12 receptor by its active metabolite. Thrombin induces platelet aggregation by binding to protease activated receptor-1 (PAR-1), and inhibition of PAR-1 has been evaluated in patients treated with clopidogrel to reduce ischemic events after acute coronary syndromes. Residual PAR-1 mediated platelet aggregation may be dependent on extent of clopidogrel response. Material and Methods: Platelet aggregation was measured in 55 patients undergoing elective PCI at 16-24 hours after 600 mg clopidogrel loading dose by light transmittance aggregometry using ADP 20 μM and thrombin receptor agonist peptide (TRAP) at 15 μM and 25 μM as agonists. Genomic DNA was genotyped for common CYP2C19 variants. Results: Increasing quartiles of 20 μM ADP induced platelet aggregation after clopidogrel loading were associated with increasing levels of TRAP mediated platelet aggregation. Patients in the highest quartile (clopidogrel non-responders) of post treatment ADP aggregation had significantly higher TRAP mediated aggregation than the patients in the lowest quartile (clopidogrel responders) [TRAP 15 μM: 79.6 ± 5% vs. 69.5 ± 8%, p < 0.001]. Conclusions: Non-responders to clopidogrel show increased residual platelet aggregation induced by TRAP, whereas clopidogrel responders exhibit attenuated response to TRAP. Addition of PAR-1 antiplatelet drugs may be most effective in patients with reduced clopidogrel response and high residual TRAP mediated platelet aggregation.

KW - aggregation

KW - clopidogrel

KW - Platelet

KW - thrombin

UR - http://www.scopus.com/inward/record.url?scp=84864409943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864409943&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2012.02.049

DO - 10.1016/j.thromres.2012.02.049

M3 - Article

C2 - 22459907

AN - SCOPUS:84864409943

VL - 130

SP - 198

EP - 202

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 2

ER -